TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current ...
Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective raised by Piper Sandler from $52.00 to $53.00 in a report published on Friday,Benzinga reports. They currently have a neutral ...
Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ...
Hosted on MSN2d
Halozyme price target lowered to $57 from $62 at Wells FargoWells Fargo lowered the firm’s price target on Halozyme (HALO) to $57 from $62 and keeps an Equal Weight rating on the shares. The firm said on ...
Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.iXkfgCgn.js ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...
Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...
Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback